Loading…
Engineers blood stem cells to evade targeted cancer therapies, enabling more precise treatment of blood cancers.
Engineers blood stem cells to evade targeted cancer therapies, enabling more precise treatment of blood cancers.
Has no product on the market and pays for trials by selling shares, so the cash it raises decides how far its development programmes can run before results arrive, and partners may share the cost.
Moat: none (IP / patents, process know-how). Novel engineered stem cell platform enabling targeted post-transplant therapy, but unproven and capital intensive.
Headquarters: Cambridge, Massachusetts, US · Founded: 2019 · Employees: 76
Size Vor Biopharma (VOR) is a United States Health Care company (Biotechnology) with a market value of $1.22B, the 2129th largest of 3,117 United States companies the cockpit tracks. Shares closed at $19.88 on 6 Nov 2026.
Performance Over six months the shares gained 17.4%, against -15.8% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Short interest Short interest is 12.6% of the free float (15 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$126,000 | -$2.89M | -$3.53M | -$3.49M | -$8.96M |
| EBITDA | -$177M | -$369M | -$118M | -$123M | -$84.5M |
| Net income | $1.35B | -$696M | -$117M | -$118M | -$92.1M |
| Free cash flow | -$120M | -$144M | -$99.9M | -$101M | -$93.6M |
| Capital expenditure | $507,000 | $941,000 | $229,000 | $1.07M | $8.46M |
| Total debt | $2.81M | $3.00M | $31.8M | $35.7M | $38.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vor Biopharma VOR | $1.22B | +17% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 7.2× | -2.9% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | $341M | -18% | +288% | -211% | 4.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VOR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -6.0% | 5th highest of 21 |
| 6-month return | +17.4% | -15.8% | 6th highest of 20 |
| Distance from 52-week high | -23.5% | -43.6% | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |